Reply to Response to "'A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses After COVID-19 Vaccination'" by Mungmunpuntipantip and Wiwanitkiton.

Masuta, Yasuhiro; Watanabe, Tomohiro; Minaga, Kosuke; Kudo, Masatoshi

Masuta, Yasuhiro; Watanabe, Tomohiro; Minaga, Kosuke; Kudo, Masatoshi.

Masuta Y; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Watanabe T; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Minaga K; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

Inflamm Bowel Dis ; 28(8): e113, 2022 08 01.

Article in English | MEDLINE | ID: covidwho-1784353

Subject(s)

COVID-19; Colitis, Ulcerative; Interferon Type I; COVID-19/prevention & control; COVID-19 Vaccines/adverse effects; Humans; Recurrence; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Colitis, Ulcerative / Interferon Type I / COVID-19 Type of study: Observational study Topics: Vaccines Limits: Humans Language: English Journal: Inflamm Bowel Dis Journal subject: Gastroenterology Year: 2022 Document Type: Article Affiliation country: Ibd

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google